Skip to content
AnalystLens

ALTRIA GROUP, INC. 8-K Report, Regulation FD Disclosure (Mar 6, 2023)

Reports
Regulation FD·Other Events·Exhibits & Filings
Filing Date
Filed March 6, 2023
Period End
March 3, 2023
Security
MO
In the record · 2016–202610-K2110-Q328-K143

MO filed 21 annual reports (10-K), 32 quarterly reports (10-Q) and 143 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’16Oct ’16
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed March 6, 2023. Cited figures are marked; the original filing is the authoritative source.

Altria Group, Inc. (MO) has announced two significant strategic moves related to the e-vapor market, signaling a shift in its product portfolio.

First, the company has exchanged its minority economic investment in JUUL Labs, Inc. for a global license to JUUL's heated tobacco intellectual property. This move effectively disentangles Altria from its previous substantial investment in JUUL while acquiring valuable technology rights. Concurrently, Altria has agreed to acquire NJOY Holdings, Inc., a prominent e-vapor product company, for approximately $2.75 billiona in cash, with potential additional payments of up to $500 million tied to FDA approvals.

This acquisition aims to secure full global ownership of NJOY's e-vapor product line, notably including the NJOY ACE, which holds FDA market authorizations. These transactions collectively demonstrate Altria's strategic intent to strengthen its position in the evolving e-vapor and heated tobacco landscape.

02—Key points

Key Highlights

  1. Altria exits its minority economic investment in JUUL Labs, Inc.
  2. Altria secures a global license to JUUL's heated tobacco intellectual property.
  3. Altria agrees to acquire NJOY Holdings, Inc. for approximately $2.75 billion in cash.
  4. Potential for an additional $500 million in cash payments to NJOY sellers contingent on FDA approvals.
  5. Acquisition provides Altria with full global ownership of NJOY's e-vapor product portfolio.
  6. NJOY ACE, a key product in the acquisition, is the only pod-based e-vapor product with FDA market authorizations.

03—Questions

Frequently Asked Questions

  1. What is the financial impact of the JUUL transaction?

    Altria will record the financial impact of the JUUL transaction in the first quarter of 2023. The details of this impact, including any gains or losses recognized, will be reflected in their upcoming financial statements.

  2. What are the key terms of the NJOY acquisition?

    Altria will acquire NJOY through a merger for approximately $2.75 billion in cash at closing. There is an additional $500 million in cash contingent on certain NJOY products receiving FDA approvals. The acquisition is subject to customary closing conditions and is not dependent on financing.

  3. What is the significance of NJOY ACE having FDA market authorizations?

    The NJOY ACE is highlighted as the only pod-based e-vapor product with market authorizations from the U.S. Food and Drug Administration (FDA). This regulatory approval is a significant competitive advantage and de-risks Altria's entry into this segment of the e-vapor market.

  4. What are the risks associated with the NJOY acquisition?

    The company notes several risks, including the potential failure to receive regulatory authorizations for NJOY products, non-compliance with regulatory requirements, failure to realize the expected benefits of the merger, adverse changes in economic or market conditions, and the outcome of any legal proceedings related to the merger.

04—Continue

← View all 8-K filings